The U.S. pharmaceutical industry continues to rely on the blood of horseshoe crabs for vital drug safety testing, a practice that has been in place for decades. This method uses Limulus Amebocyte Lysate (LAL) to detect bacterial endotoxins, ensuring the safety of medicines and medical devices. However, this reliance is facing increasing scrutiny due to ethical concerns, potential supply chain vulnerabilities, and environmental impacts on horseshoe crab populations and the ecosystems they support.
While a synthetic alternative, recombinant Factor C (rFC), has been available and widely used in Europe for years, its adoption in the U.S. has been slow. Experts cite regulatory inertia and industry resistance as primary reasons for this lag. Although the U.S. Pharmacopeia is beginning to recognize rFC, the transition is gradual. This situation highlights a broader challenge in modernizing regulatory frameworks and embracing sustainable, non-animal alternatives in critical scientific testing.
